iRhythm Technologies (IRTC) Surpasses Q2 Revenue Forecasts, Raises Outlook

iRhythm Technologies, Inc. (NASDAQ:IRTC) is one of the best Russell 2000 stocks to buy now. On July 31, the company’s management held an earnings call in which they hailed the records set in Q2 2025, as well as earnings beats. During the quarter, iRhythm’s revenue reached $186.7 million, a 26.1% year-over-year increase. The result beat analyst estimates by $12.7 million (expected: $174 million), a 7.3% positive surprise.

Adjusted EPS for the quarter was –$0.32, which was better than analyst forecasts of –$0.47; a 32.5% beat. Adjusted EBITDA came in at $15.7 million (8.4% margin), exceeding estimates of $11.82 million. Meanwhile, the operating margin improved to –10%, up from –15.5% the previous year.

The company set records for new account openings, long-term monitoring clients, and adoption among integrated delivery networks. Management also noted that international demand is strong, with progress reported in markets such as the UK, Europe, and Japan. They raised the full-year revenue guidance to between $720 million and $730 million (midpoint $725 million), up from $695 million—a 4.3% increase over prior guidance.

iRhythm Technologies, Inc. (NASDAQ:IRTC) is a digital healthcare company. It specializes in the design and commercialization of device-based technologies for ambulatory cardiac monitoring. Its flagship products—Zio XT, Zio AT, and Zio Monitor—are wearable ECG systems that enable continuous heart rhythm tracking for up to 14 days.

READ NEXT: 10 Best Energy Stocks to Buy For the Long Term and Top 10 Industrial Stocks to Buy Amid Easing Tariff Uncertainties.

Disclosure: None. This article is originally published at Insider Monkey.